Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Modeling method of mouse model for chronic contact dermatitis

A contact dermatitis and mouse model technology, applied in the field of biomedicine, can solve inappropriate problems and achieve the effect of a good screening platform

Active Publication Date: 2021-02-02
澎立生物医药技术(上海)股份有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In this case, it is inappropriate to use any of the above single models

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modeling method of mouse model for chronic contact dermatitis
  • Modeling method of mouse model for chronic contact dermatitis
  • Modeling method of mouse model for chronic contact dermatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Fifteen 7-week-old female Balb / c mice were selected. Except for the normal control group (3 mice), the other 12 mice received 30 μL of 1.3% oxazolone in acetone-olive oil solution on the front and back of the right ear as the first trial. For sensitization challenge, the day was designated as day 0. Seven days later, the right ear of all mice received again 30 μL of 0.8% oxazolone in acetone-olive oil solution as a second sensitization challenge. Thereafter, 20 μL of 0.3-0.5% mass fraction of oxazolone in acetone-olive oil solution was used for sensitization challenge every 2-3 days. Specifically, 0.5%, 0.5%, 0.5%, and 0.3%. On the 17th day, 12 mice with chronic contact dermatitis were obtained.

Embodiment 2

[0034]Four 6-week-old female Balb / c mice were selected to receive 30 μL of 1.2% oxazolone in acetone and olive oil solution on the front and back of the right ear as the first sensitization challenge, and this day was designated as day 0. Seven days later, the right ear of all mice received again 30 μL of 0.9% oxazolone in acetone-olive oil solution as a second sensitization challenge. Thereafter, 20 μL of 0.4-0.6% mass fraction of oxazolone in acetone-olive oil solution was used for sensitization challenge every 2-3 days. Specifically, 0.6% and 0.4% , 0.4%. Four mice with chronic contact dermatitis were obtained.

Embodiment 3

[0035] Example 3 Mouse Model Verification

[0036] Three days after the last sensitization challenge in Example 1, that is, on the 17th day, the 12 chronic contact dermatitis mice obtained were grouped according to the thickness of the right ear, and 9 mice with similar thickness of the right ear were selected and divided into three groups ( 3 animals in each group, the average thickness of the right ear is basically the same), two groups of them began to administer treatment on the same day, and one group used the positive control drug betamethasone, and the administration method was 0.03mg / ear topical administration, which was dissolved in In acetone, smear on the front and back of the right ear of the mice in the positive drug group; the other group uses dexamethasone, and the administration method is 2 mg / kg orally. Because contact dermatitis is currently being treated clinically, topical steroids are mainly used for symptom control, so in this example, the common topical ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a modeling method of a mouse model for chronic contact dermatitis. The modeling method is combined with onset characteristics and rules of chronic contact dermatitis. Accordingto the method, oxazolone is used for repeatedly sensitizing and attacking animals, not only can a chemical stimulation effect be achieved, but also the whole process that a patient repeatedly makes contact with allergens and is finally sensitized, and chronic contact dermatitis is caused is simulated; and the pathological change of disease parts of the animal model obtained by the method is highlyconsistent with the pathological change of the skin injury area of the patient, it is indicated that the model can be used for simulating a chronic contact dermatitis model of the clinical patient, and a better screening platform is provided for treatment drugs of chronic contact dermatitis.

Description

technical field [0001] The application belongs to the field of biomedicine, and in particular relates to a method for establishing an animal model of chronic contact dermatitis in mice induced by oxazolone. Background technique [0002] Contact dermatitis is a clinically very common disease, and its prevalence in the population is about 1.7%-6.3%. Although in most people, the symptoms of atopic dermatitis are not particularly serious, nor are they life-threatening. However, the repeated itching of the diseased part, and the ulceration and further aggravating symptoms caused by scratching often cause the patient to suffer very much. In general, it is not easy for patients to identify specific allergens and exclude them from their lives. Therefore, the patient's contact dermatitis is often protracted, which has a great impact on the quality of life of the patient. In order to alleviate the pain of patients, the development of related drugs has been optimized and in progress....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A01K67/02
CPCA01K67/02A01K2207/20A01K2227/105A01K2267/03
Inventor 杨楠付云峰刘新陈洁罗艳段继峰
Owner 澎立生物医药技术(上海)股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com